COVID-19 trials registries data warehouse

https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051522

Shintaro Tanaka

shintarou.tanaka@shionogi.co.jp

2021-08-09

Not recruiting

nonRCT

Non-randomized

Single group assignment

Open label

unclear

Prevention

1. For male, those who more than 200 mL of their whole blood or blood component has been lost within 12 weeks before consent acquisition, or those who more than 100 mL of their whole blood or blood component has been lost within 4 weeks before consent acquisition. For female, those who more than 200 mL of their whole blood or blood component has been lost within 16 weeks before consent acquisition, or those who more than 100 mL of their whole blood or blood component has been lost within 4 weeks before consent acquisition.2. Those who participated in other clinical studies within 30 days before consent acquisition, or are participating in other clinical studies except for &quot,Observational study on the evaluation of COVID-19 prevention and subjects&#39, health status after SARS-CoV-2 vaccination&quot, conducted by Shionogi &amp, Co., Ltd.

1

Shionogi & Co.; Ltd.

20

100

Japan

Healthy volunteers

N/A

7380

Antibody titer for virus neutralization activity

Not reported

[{"arm_notes": "", "treatment_id": 1911, "treatment_name": "Covid-19 vaccine", "treatment_type": "Other covid vaccine", "pharmacological_treatment": "Vaccine"}]